# IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

> **NCT02636270** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 7 (actual)

## Conditions studied

- Short Stature

## Interventions

- **DRUG:** Increlex

## Key facts

- **NCT ID:** NCT02636270
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-21
- **Primary completion:** 2022-10-14
- **Final completion:** 2022-12-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02636270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02636270, "IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02636270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*